Exploring the Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy: A Prospective Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07167446

Title field or adapter rule

{'original_value': 'Exploring the Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy: A Prospective Study', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:28.791511+00:00

Published At

2026-10-29T00:00:00+00:00

Record Updated At

2026-10-29

Source Retrieved At

2026-10-31T22:18:26.854673+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients", "Metastatic Colorectal Cancer (CRC)", "Peripheral Neuropathy Due to Chemotherapy"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-29", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07167446"

protocolSection.identificationModule.officialTitle

"Exploring the Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy: A Prospective Study"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["EARLY_PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients (protocolSection.conditionsModule.conditions)
• Metastatic Colorectal Cancer (CRC) (protocolSection.conditionsModule.conditions)
• Peripheral Neuropathy Due to Chemotherapy (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Cannabidiol (CBD)'], 'description': 'Oral hemp-derived CBD capsules, 150 mg twice daily (with titration in Cycle 1; dose reductions permitted for tolerability). Administered starting the day before oxaliplatin infusion and continued for 7 days after each chemotherapy cycle.', 'name': 'Cannabidiol (CBD)', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cannabidiol (CBD)', 'Standard of Care'], 'description': 'Standard of care oxaliplatin-based regimens per NCCN guidelines (e.g., FOLFOX or CAPEOX), administered in 2-3 week cycles for a maximum of 6 months.', 'name': 'oxaliplatin-based chemotherapy', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Cannabidiol (CBD) (protocolSection.armsInterventionsModule.interventions[].name)
• oxaliplatin-based chemotherapy (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.